Primary Recommendation

Quantum Pharma - Considerably less flannel from new CEO

February 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Quantum Pharma was founded in 2004 by two accountants, former chief executive Andrew Scaife and former finance director Martin Such. They launched the company as a supplier of unlicensed medicinal products known as “specials,” which are prescribed by a doctor for a number of chronic conditions and prepared when a licensed product is not available on the market. This is a reliable but unexciting business and their plan was to take some of the unlicenced products and convert them to licenced medicines, where margins were substantial.Their initial triumph of getting VC backers and bringing the concept to the City proved short lived as sadly the guys became a little overconfident and made unnecessary acquisitions left, righ ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Gresham Technologies - Run rate of recurring Clareti revenues +94%

Cape - Oil & gas services sector breaks recent downgrade cycle

Quantum Pharma - Gain since our February write up: 75% (October 2017)

Quantum Pharma - Bid from Clinigen (September 2017)

Quantum Pharma (June 2017)

Quantum Pharma - Sweep of board and placing (November 2016)

Quantum Pharma (June 2016)

Quantum Pharma (March 2016)

Quantum Pharma - Five more products now approved (November 2015)

Quantum Pharma - Soon-to-be prospective PE of 9.9 (October 2015)

Quantum Pharma (September 2015)

Quantum Pharma - Explosive growth trajectory (June 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X